Neumora Therapeutics (NMRA) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Telomir Pharmaceuticals (TELO) has outperformed Neumora Therapeutics (NMRA) over the past year, losing 30.3% versus a loss of 75.3%. Neumora Therapeutics is the larger company by market cap ($90.2 million vs $84.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NMRA | TELO |
|---|---|---|
| Share price | $0.4798 | $1.15 |
| Market cap | $90.15M | $84.66M |
| 1-day change | +2.46% | +2.68% |
| YTD return | -73.20% | -13.53% |
| 1-year return | -75.27% | -30.30% |
| EPS (TTM) | $-1.23 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.65 | $1.82 |
| 52-week low | $0.45 | $0.888 |
| Distance from 52-week high | -86.85% | -36.71% |
| Analyst consensus | none | none |
| Avg. price target upside | +1179.70% | +247.83% |
| Average volume | 1.19M | 97.98K |
| Shares outstanding | 187.90M | 73.62M |
| Employees | 63 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TELO has outperformed NMRA by 45.0 percentage points over the past year.
About Neumora Therapeutics
NMRA stock →Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Healthcare · Biotechnology · 63 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Healthcare · Biotechnology
NMRA vs TELO FAQ
Which is bigger, Neumora Therapeutics or Telomir Pharmaceuticals?
Neumora Therapeutics (NMRA) is larger, with a market capitalization of $90.15M compared with $84.66M for Telomir Pharmaceuticals (TELO).
Which stock has performed better over the past year, NMRA or TELO?
TELO returned -30.30% over the past 12 months, compared with -75.27% for NMRA (price return, excluding dividends). Past performance does not predict future results.
Are Neumora Therapeutics and Telomir Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.